Solvonis Therapeutics (LSE:SVNS) Net Margin %: 0.00% (As of Dec. 2025)


What is Solvonis Therapeutics Net Margin %?

Solvonis Therapeutics LSE:SVNS +5.00% Net Margin % is 0.00% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 3,028 Industrial Products companies, Solvonis Therapeutics ranks worse than 33025.07% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Solvonis Therapeutics's Net Income for the six months ended in Dec. 2025 was £-4.12 Mil. Solvonis Therapeutics's Revenue for the six months ended in Dec. 2025 was £0.00 Mil. Therefore, Solvonis Therapeutics's net margin for the quarter that ended in Dec. 2025 was 0.00%.

The historical rank and industry rank for Solvonis Therapeutics's Net Margin % or its related term are showing as below:


LSE:SVNS's Net Margin % is not ranked *
in the Industrial Products industry.
Industry Median: 4.505
* Ranked among companies with meaningful Net Margin % only.

Solvonis Therapeutics  (LSE:SVNS) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Solvonis Therapeutics Net Margin % Related Terms

Solvonis Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Solvonis Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solvonis Therapeutics Net Margin % Chart

Solvonis Therapeutics Annual Data
Trend May18 May19 May20 May21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial -86.73 -499.08 -531.52 0.00 0.00

Solvonis Therapeutics Semi-Annual Data
May18 May19 May20 May21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -574.64 0.00 0.00 0.00 0.00

LSE:SVNS vs GEV, ETN, PH: Net Margin % Comparison

For the Specialty Industrial Machinery subindustry, Solvonis Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Solvonis Therapeutics Net Margin % vs Industrial Products Industry

For the Industrial Products industry and Industrials sector, Solvonis Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Solvonis Therapeutics's Net Margin % falls into.


Solvonis Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Solvonis Therapeutics's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-5.74/0
= %

Solvonis Therapeutics's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-4.119/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Solvonis Therapeutics (LSE:SVNS) has a Net Margin % of 0.00% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Solvonis Therapeutics and its competitors. According to the industry distribution chart, Solvonis Therapeutics ranks #999999 out of 3028 companies in the Industrial Products industry.
Is Solvonis Therapeutics' Net Margin % too high?
Solvonis Therapeutics' current Net Margin % is 0.00%. Based on the distribution chart, Solvonis Therapeutics ranks #999999 out of 3028 companies in the Industrial Products industry, which is in the bottom quartile relative to peers.
How does Solvonis Therapeutics' Net Margin % compare to GEV and ETN?
According to the Industrial Products industry distribution chart, Solvonis Therapeutics ranks #999999 out of 3028 companies for Net Margin %. This places Solvonis Therapeutics in the lower half of its industry. The industry median Net Margin % is 4.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for an Industrial Products company?
The median Net Margin % among Industrial Products companies is 4.51, based on 3,028 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Solvonis Therapeutics and its competitors. For the Industrial Products industry, the median Net Margin % is 4.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solvonis Therapeutics's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solvonis Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Solvonis Therapeutics (LSE:SVNS) is currently considered Possible Value Trap. The stock's GF Value™ is £0.02, compared to a current price of £0.00 — trading 91.6% below its estimated fair value. The current Net Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Solvonis Therapeutics (LSE:SVNS), the current Net Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Solvonis Therapeutics Business Description

Other Exchanges J4I:Germany
Address Eccleston Yards, 25 Eccleston Place, London, GBR, SW1W 9NF
Solvonis Therapeutics PLC focuses on the development of therapeutic solutions. The company is engaged in the development of novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders focusing on addiction and psychiatry. The products in company's pipeline include SVN-001, SVN-002, SVN-015. SVN-114, and others.